about
Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulationNVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer modelsHepatitis B virus X protein upregulates HSP90alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2Proteome-wide lysine acetylation in cortical astrocytes and alterations that occur during infection with brain parasite Toxoplasma gondiiHeat shock proteins as danger signals for cancer detectionTel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexesIdentification of a novel HSP70-binding cochaperone critical to HSP90-mediated activation of small serine/threonine kinaseBreast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperoneTheileria-induced constitutive IKK activation is independent of functional Hsp90Hsp60 regulation of tumor cell apoptosisHsp90 binds directly to fibronectin (FN) and inhibition reduces the extracellular fibronectin matrix in breast cancer cellsHsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagyMolecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysisAn intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acidCytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancerAneuploidy: cells losing their balanceHeat shock factor 1 is a powerful multifaceted modifier of carcinogenesisMolecular clock: an anti-neo-Darwinian legacyTargeting p97 to Disrupt Protein Homeostasis in CancerMechanisms of Hsp90 regulationMLK3 Signaling in Cancer InvasionTargeting Cell Survival Proteins for Cancer Cell DeathUnfolding the Role of Large Heat Shock Proteins: New Insights and Therapeutic ImplicationsALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsStress Response Leading to Resistance in Glioblastoma-The Need for Innovative Radiotherapy (iRT) ConceptsALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceHeat shock protein 90 targeting therapy: state of the art and future perspectiveContribution of the Type II Chaperonin, TRiC/CCT, to OncogenesisHSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative NeoplasmsHsp90: A New Player in DNA Repair?The Evolution of Therapies in Non-Small Cell Lung CancerTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyMaximizing the Therapeutic Potential of HSP90 InhibitorsGanetespib: research and clinical developmentProgress of molecular targeted therapies for prostate cancersRedundancy of the genetic code enables translational pausingQuality control and fate determination of Hsp90 client proteinsTargeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseasesHeat shock proteins at the crossroads between cancer and Alzheimer's diseaseExtracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally
P2860
Q21195216-37447689-E966-4387-8DE5-55EDCABE4DD7Q21195221-FD4365CC-D763-4EFA-AE3A-A70AD591D672Q21245106-F987B5D4-A870-4862-B2D4-B350C4FA3012Q22255525-F63D4FBB-E26D-49B0-B5D5-BADA7EE0AB3FQ24273349-175B44EC-FE63-4B05-960A-0AB0089DF758Q24297874-FF48DB6C-DF78-4919-BC05-5EB399AE08DFQ24299263-613BF21F-44FA-4C84-880B-10FBFA8C429EQ24300246-7E4C00CC-D7A8-4090-8472-20F1288A4C5BQ24300863-88164FDE-268F-4107-BE39-8BC75A16496BQ24303954-76481637-290D-4749-873D-74ED7784B229Q24323386-60B84036-DC8C-4856-941D-577F262C7492Q24323790-BBB016F2-14D0-44C0-9E7E-9D2DB634CED8Q24337960-1B268FBE-693C-4C1B-A3FB-AB470CF92BC7Q24625749-9EDB66FA-1E06-4318-BFB0-9603BA672DF7Q24654354-DE11BE31-78FF-4B64-8C02-DCF58AE474FCQ24654413-259E31E7-8C13-4F7A-8E8F-8506DA1E1DD1Q24655006-B8A527BE-E6D3-4DDC-B355-43541FB788CEQ24671662-40ED869B-CDC0-4DD6-BB71-9B0715EBCD47Q26740517-79C1CA58-F440-4538-82B9-998CFB79700FQ26741834-BC69C00C-E14F-4A20-84AB-DE38D35A73C9Q26746892-746D0015-44F1-483A-B08D-D2DE59A47B5FQ26765447-8D27B7F5-7BF5-4ABB-9DA5-00B9CFA7110FQ26765920-6CA45DB2-A128-4D97-B165-F6E3B0D6D5A8Q26769879-F9DCA705-2601-48AA-9111-3C95688A17E9Q26771706-CAE9308E-CD38-4D0C-8641-0ADD2A4A1276Q26775347-CB405640-AF67-4B36-896A-0A23023A287BQ26776302-EE3A766D-0FDE-4DFD-BC4F-0EE87FB4C5BEQ26777412-E193A169-D830-4B9E-9606-3A5B4E4EE17BQ26778548-4CF16B83-2D31-4CD7-9234-1AFC70B60763Q26778944-4790A131-4F3D-41B8-BD57-2C2C85AA4B77Q26786932-0D36F6BE-D844-425C-A1DF-26D8497535BFQ26795555-B6617AB3-8FE3-4C1B-B2B8-A3498013FBF1Q26798318-5F3AA061-031E-421C-9A1E-EB5EB3837FB5Q26798645-7D045A03-8D8E-4E36-B923-446B7541D251Q26823014-4F7A5B0C-CB7F-4661-B200-C78F20FDAC3CQ26823784-AD8E8D1B-FF44-4C53-8AA0-50CC6F2A0BE9Q26853052-879418F6-61AF-4B64-942D-2B11A3208177Q26859909-9ADCA9D2-65B7-4EE7-B861-930A316E2969Q26864311-B44C909D-9B43-41CD-A632-3D8A7413D84EQ26991472-61794D04-07B2-40C1-8A98-B6DFACB79E85
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
HSP90 and the chaperoning of cancer
@ast
HSP90 and the chaperoning of cancer
@en
type
label
HSP90 and the chaperoning of cancer
@ast
HSP90 and the chaperoning of cancer
@en
prefLabel
HSP90 and the chaperoning of cancer
@ast
HSP90 and the chaperoning of cancer
@en
P3181
P356
P1476
HSP90 and the chaperoning of cancer
@en
P2093
Lindquist SL
Whitesell L
P2888
P304
P3181
P356
10.1038/NRC1716
P407
P577
2005-10-01T00:00:00Z
P5875
P6179
1009936643